Cannabidiol efficacious for lennox-gastaut drop seizures

January 26, 2018

(HealthDay)—For patients with drop seizures associated with Lennox-Gastaut syndrome, add-on cannabidiol is associated with a reduction in monthly drop seizure frequency, according to a study published online Jan. 24 in The Lancet.

Elizabeth A. Thiele, M.D., from Massachusetts General Hospital in Boston, and colleagues conducted a randomized trial at 24 clinical sites to examine the efficacy of cannabidiol as add-on therapy for drop seizures in 171 patients with treatment-resistant Lennox-Gastaut syndrome. Participants were randomized in a 1:1 ratio to cannabidiol (86 patients) or placebo (85 patients).

The researchers found that the median percentage reduction in monthly drop seizure frequency was 43.9 and 21.8 percent in the cannabidiol and placebo groups, respectively. During the 14-week treatment period, the estimated median difference between treatment groups was −17.21. Adverse events occurred in 86 and 69 percent of patients in the cannabidiol and placebo groups, respectively; most were mild or moderate. Diarrhea, somnolence, pyrexia, decreased appetite, and vomiting were the most common adverse effects. Due to , 12 patients in the cannabidiol group and one in the withdrew from the study.

"Add-on cannabidiol is efficacious for the treatment of with drop seizures associated with Lennox-Gastaut syndrome and is generally well tolerated," the authors write. "The long-term efficacy and safety of is currently being assessed in the open-label extension of this trial."

Several authors disclosed financial ties to pharmaceutical companies, including GW Pharmaceuticals, which funded the study.

Explore further: Cannabis-based medicine may cut seizures in half for those with tough-to-treat epilepsy

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Cannabis-based medicine may cut seizures in half for those with tough-to-treat epilepsy

April 18, 2017
Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy, according to new information released today from a large scale controlled clinical study ...

Cannabis derivative cannabidiol reduces seizures in severe epilepsy disorder

May 24, 2017
After years of anecdotal claims about its benefits, the cannabis derivative cannabidiol reduced seizure frequency by 39 percent for patients with Dravet syndrome - a rare, severe form of epilepsy - in the first large-scale ...

Review: cannabidiol may be beneficial for oral mucositis

February 16, 2017
(HealthDay)—Cannabidiol could be beneficial for the treatment of oral mucositis, although data on its use in dentistry are scarce, according to a review published online Feb. 12 in the Journal of Clinical Pharmacy and Therapeutics.

Clinical trials treat epilepsy patients in WNY with medical marijuana

January 22, 2016
For patients with severe forms of epilepsy that don't respond to other medications, hopes are high for marijuana as a treatment. But clinical data showing how well the drug works—and how safe it is—are sparse, experts ...

Cannabidiol benefits and mechanisms shown in mouse study of Dravet syndrome

October 10, 2017
Treatment with cannabidiol reduces some major symptoms in mice with a genetic condition recapitulating Dravet syndrome, a devastating childhood brain disorder.

Medical marijuana liquid extract may bring hope for children with severe epilepsy

April 13, 2015
A medicinal liquid form of marijuana may show promise as a treatment for children with severe epilepsy that is not responding to other treatments, according to a study released today that will be presented at the American ...

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.